ProQuad
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | ProQuad | — | 2006-04-05 | europa.eu ↗ |
Trials 12 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05630846 Comparator | Dec 2022 → Jun 2024 | measles | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00578175 Comparator | Nov 2007 → Feb 2009 | chickenpox, measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01621802 Background | Jun 2012 → Jul 2015 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01536405 Comparator | Jun 2012 → Jul 2013 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00326183 Comparator | Mar 2007 → Jan 2008 | chickenpox, hepatitis A virus infection, measles, mumps infectious disease +1 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00312858 Comparator | Apr 2006 → Mar 2008 | hepatitis A virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ProQuad | “This study is designed to evaluate the immunogenicity and safety of the investigational measles, mumps, rubella, varicella vaccine (referred to as the MMRVNS vaccine) compared...” NCT05630846 ↗17“This study will test the safety and how well the body's immune system responds to a live, but weakened varicella (chickenpox) vaccine, known as Varivax, given with and without...” NCT00258726 ↗ “frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).” PMID 17502347 ↗ May 2007 “ProQuad™” NCT00109343 ↗ |
| Known as | Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad) | “Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)” NCT00839917 ↗ |
| Known as | MMRV | “This open-label, multicenter, randomized, comparative study evaluated immunogenicity, safety and tolerability of concomitant (Group 1; n=330) vs. non-concomitant (Group 2;...” PMID 23744509 ↗ Jun 20132“Healthy children 12-to-23 months of age at 71 US sites were randomized (1:1) to receive MMRV manufactured using an alternative process (MMRVAMP) or the currently licensed MMRV.” PMID 27149048 ↗ May 2016 “Both groups received concomitantly Prevnar 13 (PCV13) and Rotateq (RV5) at 2, 3 and 4 months of age and ProqQad (MMRV) at 12 months of age.” PMID 27846055 ↗ Feb 2017 |
| Known as | MMRV (2006 process) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01536405 ↗ |
| Known as | ProqQad | “Both groups received concomitantly Prevnar 13 (PCV13) and Rotateq (RV5) at 2, 3 and 4 months of age and ProqQad (MMRV) at 12 months of age.” PMID 27846055 ↗ Feb 2017 |
| Known as | V221 | “This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.” NCT00975507 ↗ |
| Modality | Vaccine | “virus vaccine live” NCT00092430 ↗ |
| Route | Subcutaneous | “0.5-mL subcutaneous injection” NCT00109343 ↗ |